Format

Send to

Choose Destination
Eur J Clin Pharmacol. 2018 Feb;74(2):193-199. doi: 10.1007/s00228-017-2359-3. Epub 2017 Nov 13.

Comparison of cardiovascular events among treatments for overactive bladder: a Danish nationwide cohort study.

Author information

1
RTI Health Solutions, Av. Diagonal, 605, 9-1, 08028, Barcelona, Spain.
2
University of Southern Denmark, J. B. Winsløws Vej 19, 2., 5000, Odense, Denmark. jhallas@health.sdu.dk.
3
University of Southern Denmark, J. B. Winsløws Vej 19, 2., 5000, Odense, Denmark.
4
Astellas Pharma B.V., PO Box 344, 2300 AH, Leiden, The Netherlands.
5
Astellas Pharma Global Development Inc., 1 Astellas Way, Northbrook, IL, 60062, USA.

Abstract

PURPOSE:

The purpose of this study is to explore the cardiovascular safety of antimuscarinic drugs to treat overactive bladder (OAB) in Denmark.

METHODS:

This was a cohort study using data recorded in Danish registries from patients newly exposed to darifenacin, fesoterodine, oxybutynin, solifenacin, tolterodine, or trospium in 2004-2012. We estimated crude and standardized incidence rates (IRs) for acute myocardial infarction (AMI); stroke; cardiovascular mortality; major adverse cardiac events (MACE, a combined endpoint of the previous three outcomes); and all-cause death for the individual and combined drugs. We also estimated crude, standardized, and propensity score-stratified incidence rate ratios (IRRs) comparing individual antimuscarinic drugs to tolterodine as the reference.

RESULTS:

Among 72,917 new users of OAB drugs (mean age, 66 years; 60% women), the standardized IR (95% confidence interval) per 1000 person-years for current use of any OAB drug was 2.7 (2.5-2.9) for AMI, 1.3 (1.2-1.5) for stroke, 7.8 (7.5-8.1) for MACE, 4.8 (4.5-5.0) for cardiovascular mortality, and 15.2 (14.8-15.6) for all-cause mortality. Propensity score-stratified IRRs for current use (reference, tolterodine) were close to the null for all drugs and endpoints.

CONCLUSIONS:

We did not identify differences in the risk of cardiovascular events or mortality among users of individual antimuscarinic OAB drugs.

KEYWORDS:

Cardiovascular diseases; Denmark; Muscarinic antagonists; Pharmacoepidemiology; Urinary bladder, overactive

PMID:
29134254
DOI:
10.1007/s00228-017-2359-3
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Springer
Loading ...
Support Center